ArticleThe mental health clinician2017
Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature.
Article in The mental health clinician, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04701866 (Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.The Cochrane database of systematic reviews · 2021Pooled it
- Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study.Brain and behavior · 2020Trial
- The effect of ketamine on preventing postpartum depression.Journal of medicine and lifeTrial
- Proteomic patterns associated with ketamine response in major depressive disorders.Cell biology and toxicology · 2025Article
- The role of NMDARs in the anesthetic and antidepressant effects of ketamine.CNS neuroscience & therapeutics · 2024Review
- Protein quality control ofFrontiers in cellular neuroscience · 2022Review
- A 25-Year-Old Chronic Ketamine User with Urinary Symptoms; a Case Report.Archives of academic emergency medicine · 2022Article
- Context-Specific Tolerance and Pharmacological Changes in the Infralimbic Cortex-Nucleus Accumbens Shell Pathway Evoked by Ketamine.Neurochemical research · 2021Article
- An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression.Frontiers in psychiatry · 2021Article
- Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects.Translational psychiatry · 2020Article
- Pharmacological Treatments for Patients with Treatment-Resistant Depression.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Bipolar depression: a major unsolved challenge.International journal of bipolar disorders · 2020Review
- Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?Neuropsychiatric disease and treatment · 2020Article
- Dissociating the Clinical Role and Economic Value of Intranasal Esketamine.Journal of managed care & specialty pharmacy · 2020Article
- Ketamine Administration Reverses Corticosterone-Induced Alterations in Excitatory and Inhibitory Transmission in the Rat Dorsal Raphe Nucleus.Neural plasticity · 2019Article
- Reduced functional bladder capacity associated with ketamine use.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOver the past decade, ketamine has been studied for major depressive disorder and bipolar depression. Ketamine is believed to exert its antidepressant properties through N-methyl-D-aspartate receptor antagonism.
methodsStudy authors completed a literature review of seven randomized controlled trials of ketamine usage in major depressive disorder and bipolar depression.
resultsKetamine demonstrated a statistically significant improvement over placebo or midazolam in major depressive disorder. Ketamine also exhibited a statistically significant improvement over placebo in bipolar depression. DISCUSSION: Ketamine has shown promise in quickly reducing symptoms in patients with treatment resistant depression and bipolar depression. Using ketamine may be helpful for patients that have exhausted other therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.